On this episode of H2O (High On Health) we talk CBD. We discuss the science, history, regulations and what to look for when considering CBD.
For more you can message me here: https://www.facebook.com/drckchemistry/
Follow me on Instagram: https://www.instagram.com/drckscience/

References
Adams R, Hunt M, Clark JH. Structure of Cannabidiol, a Product Isolated from the Marijuana Extract of Minnesota Wild Hemp. I. Journal of the American Chemical Society. 1940;62(1):196-200.
Michoulam R, Shvo Y. Hashish. I. The structure of cannabidiol. Tetrahedron. 1963;19(12):2073-2078.
Roger A. Nicoll and Bradley E. Alger, “The Brain’s Own Marijuana,” Scientific American, December 2004.
John M. McPartland, “The Endocannabinoid System: An Osteopathic Perspective,” JOAO, October 2008.
C. Pope, R. Mechoulam, L. Parsons, “Endocannabinoid Signaling in Neurotoxicity and Neuroprotection,” in Neurotoxicology, Dec. 4, 2009.
Ethan B. Russo, “Clinical Endocannabinoid Deficiency,” Neuroendocrinology Letters Nos. , Feb-Apr Vol. 25, 2004
Piluzza G, Delogu G, Cabras A, Marceddu S, Bullitta S. Differentiation between fiber and drug types of hemp (Cannabis sativa L.) from a collection of wild and domesticated accessions. Genet Resour Crop Evol. 2013;60:2331–42. doi:10.1007/s10722-013-0001-5.
Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: the Plant of the thousand and one molecules. Front Plant Sci. 2016;7:19. doi:10.3389/fpls.2016.00019. [PubMed: 26870049]
Pellati F, Brighenti V, Sperlea J, et al. New methods for the comprehensive analysis of bioactive compounds in Cannabis sativa L. (hemp). Mol Basel Switz 2018;23.
U.S. Department of Health and Human Services. National survey on drug use and health [Internet]. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2018 Available from: https://datafiles.samhsa.gov/.
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9- tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215. doi:10.1038/bjp.2008.22. [PubMed: 17828291]
Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, et al. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol 2017;8:744. doi: 10.3389/fphar.2017.00744. [PubMed: 29109685]
Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017;8:422. doi:10.3389/fphar.2017.00422. [PubMed: 28701957]
Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sánchez de Medina V, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N, et al. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem Pharmacol. 2018;157:148–58. doi:10.1016/j.bcp.2018.08.046. [PubMed: 30194918]
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150:613–23. doi:10.1038/sj.bjp.0707133. [PubMed: 17245363]
Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. 2019;176:1455–69. doi:10.1111/bph.14440. [PubMed: 29981240]
Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 2006;372:354–61. doi: 10.1007/s00210-006-0033-x. [PubMed: 16489449]
“Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives” Am J Drug Alcohol Abuse. 2019 ; 45(6): 563–579. doi:10.1080/00952990.2019.1634086

source